opdualag-hcp-us-main-nav
opdualag-hcp-us-utility-nav

For U.S. Healthcare Professionals only

Next Page Icon

Indication

Signs, symptoms, grading, and management

Other immune-mediated adverse reactions

Signs and symptoms of other immune-mediated adverse reactions may include1

  • Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
  • Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
  • Persistent or severe muscle pain or weakness, muscle cramps
  • Low red blood cells, bruising

Management considerations1

  • Withhold or permanently discontinue Opdualag depending on severity
  • In general, if Opdualag requires interruption or discontinuation, administer 1 to 2 mg/kg/day prednisone or equivalent until improvement to Grade 1 or less
  • Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month
  • Consider administration of other systemic immunosuppressants in patients whose IMARs are not controlled with corticosteroid therapy

The following clinically significant IMARs occurred at an incidence of <1% (unless otherwise noted) in patients who received Opdualag or were reported with the use of other PD-1/PD-L1–blocking antibodies1:

Severe or fatal cases have been reported for some of these adverse reactions.

  • Cardiac/vascular: Pericarditis, vasculitis
  • Nervous system: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
  • Ocular: Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada–like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss
  • Gastrointestinal: Pancreatitis to include increases in serum amylase and lipase levels, gastritis, and duodenitis
  • Musculoskeletal and connective tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae including renal failure), arthritis, and polymyalgia rheumatica
  • Endocrine: Hypoparathyroidism
  • Other (hematologic/immune): Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection

Management considerations for immune-mediated neurological toxicities1

GRADES BASED ON
CTCAE V5.02
GRADE 1 GRADE 2 GRADE 3-4
Dose modification
with Opdualag
Continue treatment Withhold treatment* Permanently discontinue treatment
Management - Administer 1 to 2 mg/kg/day prednisone or equivalent until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.
Follow-up - Consider administration of other systemic immunosuppressants in patients whose IMARs are not controlled with corticosteroid therapy.

NCI CTCAE V5.0 GRADING OF IMMUNE-MEDIATED NEUROLOGICAL TOXICITIES3

  • GRADE 1:  Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
  • GRADE 2:  Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL
  • GRADE 3:  Severe or medically significant but not life threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL
  • GRADE 4:  Life-threatening consequences; urgent intervention indicated

In a trial that evaluated Opdualag, toxicity was graded per NCI CTCAE V5.0.1

*Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids.1

ADL=activities of daily living; IMAR=immune-mediated adverse reaction; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; PD-1=programmed cell death protein-1; PD-L1=programmed death-ligand 1.

Dosing schedule icon
Dosing Schedule

Learn more about the dosing schedule for this fixed-dose combination therapy.

Patient monitoring checklist icon
Patient Monitoring
Checklist

A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.

References:

  1. Opdualag [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Published November 27, 2017. Accessed July 19, 2024. https://ctep.cancer.gov/protocoldevelopment/‌electronic_applications/docs/‌CTCAE_v5_ Quick_Reference_8.5x11.pdf.


Legal Notice     Privacy Policy     Your Privacy Choices     Site Map

Opdualag™ and the related logo are trademarks of Bristol-Myers Squibb Company. OPDIVO®, YERVOY® and the related logos are registered trademarks of Bristol-Myers Squibb Company.

All other trademarks are the property of their respective owners.

 

1425-US-2400192 09/24